gms | German Medical Science

26. Jahrestagung der Deutschen Retinologischen Gesellschaft

Deutsche Gesellschaft für Retinologie

27.09.2013, Hamburg

Everolimus reduces the metastatic potential of human uveal melanoma cells

Meeting Abstract

  • Julia Lüke - Lübeck, Germany
  • D. Wildner - Lübeck, Germany
  • M. Lüke - Lübeck, Germany
  • S. Grisanti - Lübeck, Germany
  • A. Tura - Lübeck, Germany

Retinologische Gesellschaft. 26. Jahrestagung der Retinologischen Gesellschaft. Hamburg, 27.-27.09.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13rg28

doi: 10.3205/13rg28, urn:nbn:de:0183-13rg283

Veröffentlicht: 20. August 2013

© 2013 Lüke et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Aim: Evaluation of the effect of Everolimus on the viability, proliferation, and migration of the uveal melanoma cell line 92.1 as well as the expression of several metastatic proteins.

Methods: The 92.1 uveal melanoma cells were cultured in RPMI1640 supplemented with 10% serum and treated with Everolimus alone or combined with Rho-Kinase inhibitor H1152. Viability and proliferation were assessed by immunostaining (Ki-67, Vimentin, beta-Catenin) und des MTT-Assays. Migration was analyzed by the scratch assay on the confluent monolayers of cells grown in 6-well plates.

Results: The MTT-tests revealed a dosage-dependent decrease of proliferation of 92.1 cells after the treatment with Everolimus especially with a concentration of 100 nM. The expression of Ki-67, Vimentin and beta-Catenin as well as the cell migration into the wound area were reduced after the treatment with Everolimus.

Conclusions: Everolimus (0.1–1 μM) induces a reduction of cell survival, proliferation and migration of human uveal melanoma cells.